Pharmacogenomics Corner

Back to articles

Genotype-guided warfarin dosing: Questions persist

KEY POINT

In a series of letters recently published in New England Journal of Medicine as follow up to the COAG and EU-PACT trials, letter writers pointed out criticisms of these studies, including failure to include a broader range of genetic variants and to account for genetic diversity in patients of African descent. Trial authors responded to these questions and reinforced the need to apply study results in the context of FDA-approved language on effects of genetic variability.

SOURCES

Koller EA et al. Genotype-guided dosing of vitamin K antagonists [correspondence]. N Engl J Med. 2014;370:1761–6.